Press release
Insmed Reports First Quarter 2023 Financial Results and Provides Business Update
—Enrollment Complete in Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024—
About this update from Insmed Incorporated
[{"type":"text","content":"—Enrollment Complete in Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis; Topline Data Readout on Track for Second Quarter of 2024—\n—Company to Provide Detailed Update on Early-Stage Research Programs on May 8, 2023—\n—Company on Track to Share Topline Data from Post-Marketing ARISE Study of ARIKAYCE® (amikacin liposome inhalation suspension) in Third Quarter of 2023—\n—ARIKAYCE Total Revenue of $65.2 Million for the First Quarter of 2023, Reflecting 23% Annual Growth Over the First Quarter of 2022—\n—Company Reaffirms Full-Year 2023 Guidance for Global ARIKAYCE Revenues of Between $285 Million and $300 Million—\nBRIDGEWATER, N.J., May 4, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a business update.\n\"Insmed began 2023 with solid momentum, demonstrated by a strong quarter of global revenues from our commercial business and continued execution of our clinical development pipeline of mid-to-late-stage assets,\" commented Will Lewis, Chair and Chief Executive Officer of Insmed. \"In the first quarter, we achieved our goal of enrollment completion of adult patients in the Phase 3 ASPEN trial. The pace of enrollment and widespread geographic reach of this study speak to the global enthusiasm for this program as well as the tireless efforts of the Insmed teams that facilitated this significant accomplishment. In parallel, we also continue to advance our early-stage research efforts. I am tremendously excited to debut several components of our early-stage platforms at our upcoming research day, including the indications, development candidates, proprietary technologies, and preclinical data to support our efforts. Importantly, the event will also allow us to showcase some of the Insmed team leaders who are driving innovation in the treatment of serious and rare diseases.\"\nRecent Pillar Highlights \nPillar 1: ARIKAYCE \nARIKAYCE global revenue grew 23% in the first quarter of 2023 compared with the first quarter of 2022, reflecting strong performance in the U.S., as well as the ongoing launches in Japan and Europe.Insmed continues to advance the post-marketing, confirmatory trial program for ARI...